Alvotech (ALVO) has entered into supply and commercialization agreements with Sandoz (SDZ.SW) covering multiple biosimilar candidates in Canada, and in Australia and New Zealand. Sandoz will be responsible for regulatory submissions, commercialization and distribution in the respective jurisdictions. Alvotech will retain responsibility for development, global clinical activities and manufacturing and will supply finished product to Sandoz.
In Canada, the agreement covers one biosimilar candidate in ophthalmology supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, the deal encompasses three biosimilar candidates across immunology and gastroenterology.
Sandoz is currently trading at 60.72 Swiss francs, down 0.75%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.